what are the side effects of tirzepatide vs semaglutide Comparing and for Weight Loss Semaglutide vs Tirzepatide for Weight

For example, major abnormalities in AD brains include decreased mRNA and protein expression levels of insulin, insulin receptors, insulin receptor substrate 1 (IRS1) and IGF1/2, in addition to reduced protein indicators of downstream insulin signaling activity (including phosphorylated AKT (pAKT) and phosphorylated GSK3), tau mRNA, and increased amyloid precursor protein levels

What is BPC157, and why are people using it

It improves insulin sensitivity through both GLP-1 and GIP receptor activation

Also, why are they using the SELECT trial population which focused on cardiovascular disease (and which heavily skewed toward both cis-male and white, average age 61.6, all participants had to have existing cardiovascular disease and not have Type 2 Diabetes,) to claim long-term weight loss rather than talking about the STEP trial population (which while heavily skewed toward cis-woman and even more skewed white) had an average age of 47.3 and, oh yeah was actually about weight loss (and which I wrote about in detail here)

Study participants We identified all adult (aged 20 years) patients with NAFLD and type 2 diabetes who had newly started treatment with non-insulin glucose-lowering drugs (metformin, GLP-1RAs, SGLT2 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, acarbose or dipeptidyl peptidase-4 inhibitors) between 1 January 2013 and 31 December 2021